Showing: 1 - 10 of 24 RESULTS

Launch a Global Medical Career with Manipal’s American University of Antigua, College of Medicine

Medical students can be an efficient contingency workforce, provided their lack of training is suitably addressed. Being capable and ready to respond to COVID-19 like pandemic situation needs crucial emphasis on disaster management and emergency medicine. The world is faced with the reality of the shortage of physicians and healthcare providers due to the challenges posed by the current epidemiological peak. From the larger perspective, it is about how the shortage of physicians worldwide is going to impact the global health scenario. A lack of training renders medical students non-essential to patient care; on the other hand, clinical training is essential to generate future responders against COVID-19. What should be the focus of medical institutions and aspiring medical students?

Manipal’s American University of Antigua College of Medicine (AUA) is one such renowned institute in the Caribbean that helps students from different corners of the world to fulfill their dreams of becoming doctors. For nearly two decades, the university is training future physicians and offering a Doctor of Medicine (MD) degree. Gaining Experience in global healthcare is the way forward. AUA provides knowledge on global healthcare through its Global Health Track, which is conducted in collaboration with Florida International University (FIU). The purpose of the Global Health Track is to support and guide students in developing expertise in global health issues with the goal of subsequent career involvement involving patient care, service, policy making, research and education at a global level. 

Not all international medical universities and schools provide the opportunity to practice medicine in the US, Canada, the UK as well as in India. AUA’s curriculum is evaluated regularly to ensure that it is as per the standards of its USA and Canadian counterparts. AUA has collaborations/affiliations with many foreign universities like Florida International University (in the US), The University of Warwick (in the UK), and many others. Surrounded by beautiful nature with warm hospitality received from the people of the Caribbean region, AUA surely stands out to be a place to build a career in medicine and more than 3,000 students of AUA have graduated and are practicing in the US, Canada and the UK.

Manipal’s AUA emphasizes the need for well-rounded doctors. Hence, equal importance is given to the academic performance as well as emotional intelligence. The admission process is holistic that considers more than just the test scores

Alumnus Dr. Nandita Mahajan shares, “If anyone is planning to go for higher education in medicine, they should choose to go to AUA.”

The alumni of Manipal’s AUA stand testimonial to the difference being made by this institution in India as well as India’s contribution to global healthcare. The choice is usually driven by: greener pastures, studying abroad, acquiring a mere medical degree or contributing towards the larger purpose of improving the global healthcare scenario. 

Another alumnus Dr. Nandini Chattopadhyay reminisces, “The teaching that one receives in pre-clinical sciences in AUA, lay the foundation for clinical sciences. Everybody in AUA is always eager to help in

Tyme Technologies to Present at Jefferies Virtual Global Healthcare Conference on November 17-19, 2020

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will present at the Jefferies Virtual Global Healthcare Conference on November 17-19. In one-on-one sessions, the Company will present its corporate overview for fiscal year 2021 with a special focus on multiple growth opportunities driven by advances in the science of cancer cell metabolism, SM-88 (racemetyrosine) late-stage trials in pancreatic cancer, SM-88 HopES trial in ultra-rare metastatic sarcoma, proof-of-concept RESPOnD™ trial evaluating TYME-19 in COVID-19, and expanding clinical plans for its cancer-metabolism pipeline candidate SM-88 in prostate, breast and hematological cancers.

Event: Jefferies Virtual Global Healthcare Conference
Place: Waldorf Hilton, London
Presentation Date: November 17-19, 2020
Format: One-on-one sessions

The presentation will be accessible on the events page under the investor relations section of Tyme Technologies’ website at www.tymeinc.com.

About SM-88

SM-88 is an oral investigational modified proprietary tyrosine derivative that is believed to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious grade 3 or higher adverse events. Learn more.

About TYME-18

TYME-18 is composed of a proprietary surfactant delivery agent with a specific sulfonic acid component. It is designed for intra-tumoral administration of difficult to treat tumors and leverages the acidic tumor microenvironment and signaling pathways to kill cancer cells. TYME-18 is distinct in composition, but like SM-88, aims to leverage susceptibilities of a cancer that are related to its altered metabolism. Initial preclinical data for TYME-18 in animal tumor models demonstrate rapid and complete tumor regression, with no reported local or systemic toxicities. TYME-18 continues to be studied as a potential therapy for difficult to treat tumors that may not be eligible for surgical or other interventions. Learn more.

About TYME-19

TYME-19 is a potent, well characterized synthetic antiviral bile acid that is being evaluated as a potential oral therapy for COVID-19. In preclinical testing, TYME-19 repeatedly prevented COVID-19 viral replication without attributable cytotoxicity in treated cells. COVID-19 hijacks a cell’s ability to make proteins and lipids and divert these processes to make viral proteins and lipids in order to reproduce. COVID-19 accomplishes this by inducing stress in the endoplasmic reticulum (ER), where cells process proteins, which enables the virus to remodel protein and lipid synthesis. In preclinical testing, TYME-19 has been shown to counteract these effects, preventing viral replication, by reducing ER stress. TYME-19 is believed to physically degrade viruses by solubilizing the protective lipid layer and other structural components, which prevent a virus from binding to and infecting a cell.

About TYME-88-Panc Pivotal Trial

The TYME-88-Panc pivotal trial applies the latest advances in the field of cancer metabolism by evaluating the efficacy and safety of an oral investigational compound that targets the metabolic mechanisms of the

Global Disposable Tweezers Market to Surpass US$ 380.6 Million by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global disposable tweezers market is estimated to be valued at US$ 276.0 million in 2020 and is expected to exhibit a CAGR of 5.30% over the forecast period (2020-2027).

Key Trends and Analysis of the Global Disposal Tweezers Market:

Global disposable tweezers market is expected to have significant growth, owing to increase in the surgical procedures and thus driving the growth of disposable tweezers market. According to US National Library of Medicine report published in 2016, stated that every year till 2016 approximately 310 million of individuals undergo surgical treatments due to various health conditions such as cancers, cardiovascular diseases, and oral diseases.

Moreover, global disposable tweezers market is going to witness significant growth owing to various research institutes and academic institutes are taking initiatives in field of disposables market. For instance, in 2017, UC San Diego Health, the academic health system of the University of California and academic hospital system in San Diego, suggested the pharmacy stores and retail stores in US to include following medical and surgical equipment first health kit. Medical and surgical equipment included in list were sterile gauge pads, rectangular bandages, pair of plastic tweezers and forceps and one breathing barrier.

Among region, Europe has increasing prevalence of oral diseases such periodontitis, and tooth decay are leading to rise in use of surgical equipment such as tweezers, dental glasses, these factors are expected to drive the disposable tweezers market in the region. According to World Health Organization report published in 2016, stated that approximately 20% to 90% of children of age below 6 years are suffering from dental caries and undergo procedures for removal of tooth decays and approximately 5% to 20% of adults are suffering from periodontitis.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4228

Key Market Takeaways:

The global disposable tweezers market is expected to exhibit a CAGR of 5.30% over the forecast period, as increasing prevalence of dentistry procedures, increasing initiatives by research institutes for use of surgical equipment and increasing prevalence of surgical procedures.

Competitive Landscape:

Key players operating in the global disposable tweezers market include Burkle Inc, Sampling Systems Ltd, TIGA-MED Germany GmbH, MECO Instruments Pvt. Ltd, Arrowhead Forensics, 3M Healthcare, Cole-Parmer, Caplugs Evergreen, MilliporeSigma, and Changzhou Yuekang Medical Appliance Co., ltd.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4228

Market Segmentation:

  • Global Disposable Tweezers Market, By Product Type :

  • Global Disposable Tweezers Market, By Application:

    • Dental

    • Surgical

    • Forensic

    • Others

  • Global Disposable Tweezers Market, By Distribution Channel:

    • Hospital Pharmacies

    • Retail Pharmacies

    • Online Pharmacies

  • Global Disposable Tweezers Market, By Region:

    • North America

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Rest of Latin America

    • Europe

      • Germany

      • U.K.

      • France

      • Italy

      • Spain

      • Russia

      • Rest of Europe

    • Asia Pacific

      • China

      • India

      • Japan

      • Australia

      • South Korea

      • ASEAN

      • Rest of Asia Pacific

    • Middle East

      • GCC

      • Israel

      • Rest of Middle East

    • Africa

      • South Africa

      • Central Africa

      • North Africa

Related Market Intelligence Report:

Australia Reprocessed Medical Devices Market, By Device (Gastroenterology Devices, Cardiology Devices, Laparoscopy Devices, Orthopedic/ Arthroscopic Devices, ENT Devices, Others), By Classification (Critical,

Global Amitriptyline Market to Surpass US$ 762.6 Million by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global amitriptyline market is estimated to be valued at US$ 527.4 million in 2020 and is expected to exhibit a CAGR of 5.3% during the forecast period (2020-2027).

Key Trends and Analysis of the Global Amitriptyline Market:

Various research institutes are studying the effect of amitriptyline for various disease indications, which is expected to drive the growth of global amitriptyline market. For instance, in April 2016, Boston Medical Center has initiated phase 2 clinical study to compare the effectiveness of amitriptyline versus placebo (inactive medication) in treating chronic laryngitis. The study is expected to complete in October 2022.

The increasing prevalence of depression or bipolar disorders is expected to drive demand for tricyclic antidepressants such as amitriptyline, and thereby contribute to the growth of the global amitriptyline market. According to the Global Burden of Disease Collaborative Network, in 2017, the prevalence of bipolar disorder ranged from 0.3% to 1.2% by country and around 46 million people suffered from the bipolar disorder worldwide. Bipolar disorder is a brain disorder, also known as manic illness that affects the mood, energy level, and other activities.

Moreover, the increasing prevalence of migraine is another factor contributing to growth of the amitriptyline market. According to Migraine Research Foundation, migraine is the third most common disease in the world, and has affected 39 million men, women and children in the U.S. and 1 billion worldwide in 2019.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4226

Key Market Takeaways:

The Global Amitriptyline Market is expected to exhibit a CAGR of 5.3 % during the forecast period, due to increasing prevalence of neuropathic pain, and migraine.

Among regions, Asia Pacific is expected to witness significant growth in the global Amitriptyline Market during the forecast period owing to presence of local players in the region such as ALPIC BIOTECH (India), Dycine Pharmaceuticals Limited, Mesmer Pharmaceuticals, and other companies offering amitriptyline.

Competitive Landscape:

Key players operating in the Global Amitriptyline Market are Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Sandoz Inc., Sun Pharmaceutical Industries Inc., Vintage Pharmaceuticals Inc., Zydus Pharmaceuticals USA Inc., Watson laboratories Inc., and Torrent Pharmaceuticals Ltd.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4226

Market Segmentation:

Related Market Intelligence Report:

Collagen Filler Market, by Product Type (Collagen with PMMA and Collagen without PMMA), by Source (Bovine, Porcine, and Others), by Application (Face Rejuvenation, Wrinkles, Scar Treatment, Lip Treatment, Cellulite Reduction, and Others), By End User (Hospitals, Dermatology Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Read more: https://www.coherentmarketinsights.com/market-insight/collagen-filler-market-4209

Softgel Tumble Dryer Market, by Instrument Type (Standard Tumble Dryer and Continuous Tumble Dryer), by End User (Pharmaceutical Companies, Health Supplements Companies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Read more: https://www.coherentmarketinsights.com/market-insight/softgel-tumble-dryer-market-4208

North America E-pharmacy Market, by Product Type (Prescription (Rx) and Over-the-counter) and by Country

Pamela M. Sutton-Wallace Appointed to J2 Global Board of Directors

J2 Global, Inc. (NASDAQ: JCOM), a leading Internet information and services company, today announced the appointment to its board of directors of Pamela M. Sutton-Wallace, MPH, an experienced healthcare executive who has worked in several leading academic medical centers.

“We are delighted to have Pam join our Board of Directors,” said J2 Global Board Chairman Richard Ressler. “She is a nationally recognized leader in healthcare who will bring deep operating and strategic expertise to our Board.”

Pam brings more than 25 years of healthcare industry experience and currently serves as Senior Vice President and Regional Chief Operating Officer of New York Presbyterian. Previously, Pam was Chief Executive Officer at the University of Virginia Medical Center. Prior to that, Pam served as Senior Vice President of Hospital Operations at Duke University Hospital, where she also held leadership positions across the Duke University Health System. Pam earned a Master’s of Public Health from Yale University School of Public Health and a Bachelor of Arts in Political Science and African-American Studies from Washington University.

“Given the importance of healthcare within J2 Global’s portfolio, Pam’s wealth of experience at some of the world’s most renowned health systems will make her a valuable addition to our company,” said J2 Global CEO Vivek Shah.

“I am thrilled to join J2 Global’s Board of Directors,” said Sutton-Wallace. “With the healthcare industry continuing to adopt and integrate information technology, this is an ideal time to be part of an organization providing digital solutions to patients and healthcare professionals.”

About J2 Global®

J2 Global, Inc. (NASDAQ: JCOM) is a leading Internet information and services company consisting of a portfolio of brands including IGN, Mashable, Humble Bundle, Speedtest, PCMag, Offers.com, Spiceworks, Everyday Health, BabyCenter and What To Expect in its Digital Media segment and eFax, eVoice, iContact, Campaigner, Vipre, IPVanish and KeepItSafe in its Cloud Services segment. J2 Global reaches over 230 million people per month across its brands. As of December 31, 2019, J2 Global had achieved 24 consecutive fiscal years of revenue growth. For more information, visit: www.j2global.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005125/en/

Contacts

Rebecca Wright
(212) 503-5247
J2 Global, Inc.
[email protected]

Source Article

China is doubling down in the global push for a coronavirus vaccine

And while the successful development of a vaccine would not preclude other countries from continuing to pursue their own research, China has placed special emphasis on being first.

As of October, four of the 10 Covid-19 vaccine candidates that have entered Phase 3 clinical trials worldwide — the last and most important step of testing before regulatory approval is sought — were developed by Chinese companies.

Two are from China National Biotec Group (CNBG), a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm). Another candidate, CoronaVac, was developed by drugmaker Sinovac Biotech, with the remaining one jointly developed by the Chinese military-linked Beijing Institute of Biotechnology and vaccine company CanSino Biologics.

Two coronavirus vaccine candidates from the China National Biotec Group (CNBG) are now in phase 3 clinical trials.

CNBG Chairman Yang Xiaoming said last month that the progress of its vaccines was going “faster than expected.” The company has carried out Phase 3 trials in countries including the United Arab Emirates, Bahrain, Peru, Morocco, and Argentina, with a total of 42,000 participants.

“We’re only one last mile away from eventual success,” he recently told a bioindustry conference in the Chinese city of Wuhan, where the coronavirus was first detected last December.

Wu Guizhen, the chief bio-safety expert at China’s Disease Control and Prevention Center, told state broadcaster CCTV last month that the country’s coronavirus vaccines could be ready for general public use as early as November.

“I believe it’s very likely they’ll be the first to announce the successful development of a vaccine,” said Yanzhong Huang, a senior fellow for global health at the Washington-based Council on Foreign Relations.

“But the key question is how well the international society, especially the scientific community, will recognize it.”

“Spirit of sacrifice”

A vaccine usually takes years to develop. But to stop a virus that has killed more than a million people worldwide, scientists are developing Covid-19 vaccines at unprecedented speed. In China, efforts to ramp up that process have included the controversial testing of hundreds of thousands of people outside the normal regulatory approval process.

Since July, Chinese drug makers have been administering experimental vaccines on people working in “high-risk” professions — including medical workers and border agents — under a government-approved emergency use program, which allows vaccine candidates to be used on a limited scale before their safety and efficacy have been fully proven by clinical trials.

The vaccine candidates approved for emergency use are still in Phase 3 trials. Some experts worry that fast-tracking the normal approval process could potentially expose participants to unknown side effects, and Chinese drug makers are taking risks that contravene international ethical and safety norms.

“Despite official claims that the vaccines are safe and effective, it may not be a wise decision to inoculate so many people on such a large scale before systematic data from Phase 3 clinical trials become available,” said Huang, the global health expert.

Yet Chinese drug companies were already taking controversial and risky steps months before the launch of the emergency use program.

Yang, the CNBG chairman, told a conference in Wuhan last month that

China joins WHO’s plan for global distribution of COVID-19 vaccine

Oct. 9 (UPI) — China on Friday said it has joined a World Health Organization-led initiative that aims to manufacture and provide equitable access to a COVID-19 vaccine.

Hua Chunying, a spokeswoman for China’s foreign ministry, said the Asian nation signed an agreement with Gavi on Thursday to join COVAX, the vaccine pillar of the WHO’s Access to COVID-19 Tools Accelerator program.

Launched in April by the WHO, the ACT Accelerator aims to ramp up development, production and equitable distribution of COVID-19 tests, treatments and vaccines, and is co-led by the U.N. health body, Gavi and the Coalition for Epidemic Preparedness Innovations.

Hua did not state China’s financial contribution to the program but said it pledges to make domestically developed vaccines a public resource.

“This is an important step China has taken to uphold the concept of a shared community of health for all and to honor its commitment to turn COVID-19 vaccines into a global public good,” Hua said in a statement. “We are taking this concrete step to ensure equitable distribution of vaccines, especially to developing countries, and hope more capable countries will also join and support COVAX.”

As of Friday, more than 150 economies equalling nearly two-thirds of the world’s population have signed commitment agreements to the COVAX Facility in its effort to ensure low- and middle-income countries have equitable access to a vaccine when one is developed.

The United States, which has formally requested to leave the WHO, has declined to participate in the effort, as it accuses the U.N. health body of colluding with China in its efforts to cover up its initial outbreak of the virus late last year.

“We will not be constrained by multilateral organizations influenced by the corrupt World Health Organization and China,” Judd Deere, a spokesman for the White House, said early last month.

In late August, WHO Director-General Tedros Adhanom Ghebreyesus said more than 170 nations were in talks to join the program, explaining that the plan consists of delivering at least 2 billion doses of a COVID-19 vaccine by the end of next year with a global rollout to begin with those who are at the greatest risk.

“There is light at the end of the tunnel,” said Tedros, who has warned against so-called vaccine nationalism.

Gavi said Thursday it has raised roughly $1.8 billion, nearly reaching its goal of $2 billion by the end of this year for the program.

Sign up for our daily Top News Newsletter

Source Article

WHO reports record one-day rise in global coronavirus cases amid European outbreak

By Lisa Shumaker

(Reuters) – The World Health Organization reported a record one-day increase in global coronavirus cases on Thursday, with the total rising by 338,779 in 24 hours led by a surge of infections in Europe.

Europe reported 96,996 new cases, the highest total for the region ever recorded by the WHO.

Global deaths rose by 5,514 to a total of 1.05 million.

The previous WHO record for new cases was 330,340 on Oct. 2. The agency reported a record 12,393 deaths on April 17.

As a region, Europe is now reporting more cases than India, Brazil or the United States.

India reported 78,524 new cases, followed by Brazil at 41,906 and the United States with 38,904 new infections, according to the WHO, whose data lags the daily reports by each country.

According to a Reuters analysis of more recent country data, COVID-19 infections are rising in 54 countries, including surges in Argentina, Canada and much of Europe. (Graphic: https://tmsnrt.rs/34CabCf)

Infections in the United Kingdom have reached record levels with over 17,000 new cases reported on Thursday.

“We are seeing a definite and sustained increase in cases and admissions to hospital. The trend is clear, and it is very concerning,” said Dr Yvonne Doyle, medical director for Public Health England.

France’s new daily COVID-19 infections remained above the record 18,000 threshold for the second day on Thursday with new measures to curb the outbreak expected.

The average number of new infections reported in Belgium has been increasing for seven days straight and Germany reported its biggest daily increase in new cases since April on Thursday.

While India still leads in the globe in most new cases reported per day, new infections are down 20% from its peak.

In the United States, which has the largest total number of cases and deaths in the world, new infections are edging higher along with the most hospitalized COVID-19 patients since early September.

(Reporting by Lisa Shumaker in Chicago, Editing by Franklin Paul, Richard Chang and David Gregorio)

Source Article

Global Phased Array Ultrasonic Transducer Market to Surpass US$ 729.1 Million by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global phased array ultrasonic transducer market is estimated to be valued at US$ 525.6 million in 2020 and is expected to exhibit a CAGR of 4.80 % over the forecast period (2020-2027).

Key Trends and Analysis of the Global Phased Array Ultrasonic Transducer Market:

The global phased array ultrasonic transducer market is expected to show significant growth during the forecast period, owing to key companies focusing on product launches and product approvals to strengthen their position in the phase array ultrasonic transducer market. For instance, in 2017, Alpinion Medical Systems, one of South Korea’s global medical device manufacturers, launched E-CUBE 8, a smart, reliable medical device product with developed convex and phased array transducers of PowerView technology used for high performance with high quality medical imaging and multi-purpose utility in medical imaging.

Moreover, increasing incidence of heart disease conditions such as heart attack, coronary heart conditions, and hypertension are leading to rising cardiac examinations, which is expected to drive the phase array ultrasonic transducer market growth. For instance, according to the Centers for Disease Control and Prevention report, in 2017, around 2 in 10 deaths are caused due to coronary artery disease in adults less than 65 years old in the U.S. and approximately 1 in 5 people below the age of 65 suffer from silent heart attack.

Among region, North America is expected to register higher growth rate, owing to increasing innovations and development of advanced technology in phased array ultrasonic transducers. For instance, in 2019, Butterfly Network, a medical device company in the U.S., developed an ultrasonic transducer Butterfly IQ, which can be coupled with 10 approved android devices of Samsung and Google pixel. This innovation is changing the traditional way of medical imaging procedures, as Butterfly IQ is a portable ultrasonic medical device, which has enhanced compatibility with android phones, thus allowing greater accessibility for healthcare professionals.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4212

Key Market Takeaways:

The global phased array ultrasonic transducer market is expected to exhibit a CAGR of 4.80 % over the forecast period, owing to increasing product launches, product approvals, and rising innovation in development of advanced technology in phased array ultrasonic transducer medical imaging procedures

Competitive Landscape:

Key players operating in the global phase array ultrasonic transducer market include B K Medical Systems Inc, Koninklijke Philips N.V., GE Healthcare, Spacelabs Healthcare, SonoScape Medical Corp, Edan Instruments Inc, Samsung Healthcare, Mindray Medical International Limited, Esaote, FUJIFILM Medical Systems, Siemens Healthineers AG, Canon Medical Systems Corporation, and Butterfly Network Inc.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4212

Market Segmentation:

  • Global Phased Array Ultrasonic Transducers, By Type:

    • Linear Array

    • Annular Array

    • Circular Array

  • Global Phased Array Ultrasonic Transducers, By Application:

    • Cardiovascular

    • Neurological

    • Renal

    • Gynecology

    • Others

  • Global Phased Array Ultrasonic Transducers, By End User:

  • Global Phased Array Ultrasonic Transducers, By Region:

    • North America

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Rest of Latin America

    • Europe

      • Germany

      • U.K.

      • France

      • Italy

      • Spain

      • Russia

      • Rest of Europe

    • Asia Pacific

      • China

      • India

      • Japan

      • Australia

Global Collagen Filler Market to surpass US$ 648.1 Million by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global collagen filler market is estimated to be valued at US$ 648.1 million in 2020 and is expected to exhibit a CAGR of 7.4 % during the forecast period (2020-2027).

Key Trends and Analysis of the Global Collagen Filler Market:

Key companies are focusing on research and development activity and technological advancement in collagen filler is expected to drive the global collagen filler market growth. For instance, in September 2020, CollPlant, an aesthetic medicine company, presented the overview of a plant-derived recombinant human collagen for anti-ageing therapies at the Science of Aging Virtual Symposium 2020 which is a symposium event for showcasing innovation in the field of aesthetic medicine.

Moreover, increasing cosmetic procedures such as face lifts, wrinkle removal, breast augmentation, and lip treatments are expected to drive the global collagen filler market growth. For instance, according to American Society of Plastic Surgeons Report 2020, in 2019, 123,685 face lift procedures and around 37% of soft filler injection were used for treatment of various skin conditions such as skin ageing, wrinkles and face lift procedures across the globe.

Furthermore, various initiatives have been taken by regulating bodies to ensure efficient use to synthetic and cosmetics products for safer use of dermal fillers and to avoid side effects. For instance, in 2018, the US Food Drug and Administration approved temporary/absorbable dermal fillers for correction of moderate to severe face wrinkles, skin folds and unapproved dermal fillers for breast augmentation, size of buttocks, enhance fullness of feet and dermal implants into the bone, tendon, ligament and muscle.

Among regions, the North America market is expected to register highest market share owing to an increase in plastic surgery procedures such as face rejuvenations, lip treatments and temporary procedures such as face line corrections. According to the American Society of Plastic Surgeons report of May 2020, 1.8 million plastic surgeries were performed by certified plastic surgeons in 2018.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4209

Key Market Takeaways:

The global collagen filler market is expected to exhibit a CAGR of 7.4% during the forecast period owing to increasing on research and development along with technological advancement in collagen fillers along with increasing number of cosmetic procedures such as face lifts, wrinkle removal, face rejuvenation and lip treatments.

Competitive Landscape:

Key players operating in the global collagen filler market are Allergan, Inc., Johnson & Johnson, Collplant Holdings Ltd, Ortho Dermatologics, Inc., Suneva Medical, Inc., Merz Pharma GmbH & Co. KGaA, Surgical Specialties Corporation, Sinclair Pharma, Inamed GmbH, and Endo International plc.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4209

Market Segmentation:

Related Market Intelligence Report:

Ischemia Reperfusion Injury Therapeutics Market, by Indication (Heart Injury, Kidney Injury, Intestine Injury, and Other Injury), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Read more: https://www.coherentmarketinsights.com/market-insight/ischemia-reperfusion-injury-therapeutics-market-4105

About Us:

Coherent Market Insights is a global market intelligence and